|
|
Article: Highlights of first PDCO meeting of 2009.
- Article from:
- Pharma Marketletter
- Article date:
- January 26, 2009
CopyrightCOPYRIGHT 2009 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
At its first meeting of the new year, the European Medicines Agency's (EMEA) Pediatric Committee (PDCO) adopted opinions agreeing pediatric investigation plans (PIPs) for the following medicines:
- anastrozole from the UK's AstraZeneca, and iron, aqua carbonate hydroxy oxo starch sucrose complex from Swiss drug major Novartis, in the therapeutic area of endocrinology-gynecology-fertility-metabolism;
- an antigen of pre-pandemic strain A/Vietnam/1203/2004 propagated in Vero cells from US health care firm Baxter, in the therapeutic area of vaccines;
- asenapine maleate from US drug major Schering-Plough, in the therapeutic area of psychiatry;
...